Compare SEM & OGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEM | OGN |
|---|---|---|
| Founded | 1996 | 1923 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2009 | N/A |
| Metric | SEM | OGN |
|---|---|---|
| Price | $14.94 | $7.18 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 3 | 5 |
| Target Price | ★ $16.33 | $14.10 |
| AVG Volume (30 Days) | 1.0M | ★ 4.6M |
| Earning Date | 02-19-2026 | 02-12-2026 |
| Dividend Yield | ★ 1.67% | 1.12% |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.87 | ★ 1.91 |
| Revenue | $5,368,760,000.00 | ★ $6,301,000,000.00 |
| Revenue This Year | $5.53 | N/A |
| Revenue Next Year | $4.33 | N/A |
| P/E Ratio | $19.68 | ★ $3.73 |
| Revenue Growth | ★ 45.29 | N/A |
| 52 Week Low | $11.65 | $6.18 |
| 52 Week High | $20.83 | $17.23 |
| Indicator | SEM | OGN |
|---|---|---|
| Relative Strength Index (RSI) | 54.32 | 48.28 |
| Support Level | $14.73 | $7.01 |
| Resistance Level | $15.18 | $7.21 |
| Average True Range (ATR) | 0.30 | 0.21 |
| MACD | -0.08 | 0.05 |
| Stochastic Oscillator | 20.64 | 57.43 |
Select Medical Holdings Corp is a healthcare company that operates through three segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics. Critical illness recovery hospitals which derives maximum revenue consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. The rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services.
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.